港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

恆瑞醫藥

65.200

-0.650-0.99%

成交量：127.64萬

成交額：8,303.90萬

市值：4,327.32億

市盈率：57.29

高：66.200

開：66.000

低：64.500

收：65.850

52周最高：95.200

52周最低：52.500

股本：66.37億

香港流通股本：2.58億

量比：0.42

換手率：0.49%

股息：- -

股息率：- -

每股收益(LYR):1.138

淨資產收益率：14.34%

總資產收益率：8.37%

市淨率：6.39

市盈率(LYR):57.29

市銷率: 12.27

資料載入中...

總覽公司新聞資訊公告

世界腎臟日｜警惕「沉默殺手」，藥企競速「護腎」

21世纪经济报道

14億歐元BD終止！恒瑞被默克"退貨"的背後……

穩字當頭：恒瑞醫藥換屆稍欠鋭氣

馮佶，恒瑞醫藥女總裁榮登2026「福布斯中國傑出商界女性100」排行榜

北京药研汇

今日，康寧傑瑞官宣新CTO！來自恒瑞

恒瑞醫藥海外大單告吹

股市动态分析

恒瑞醫藥：注射用SHR-9803獲臨床試驗批准

南方财经网

恒瑞醫藥：董事會會議通告

香港交易所

每日沽空追蹤 | 恒瑞醫藥 03月11日沽空量成交17.64萬股，沽空比例為13.49%

恒瑞醫藥03月11日主力淨流出114.2萬元散户資金買入

「醫藥一哥」被放鴿子，又一個國產創新藥BD交易遭「退貨」

北京药研汇

翰森製藥、恒瑞醫藥等齊發力，國產GLP-1類減重藥加速「破圈」

減重大戰再添中國玩家：翰森奧萊泊肽III期成功，國產GLP-1/GIP雙靶點加速入場

多家藥企臨床獲批 / 受理，創新藥行情要啓動？

標普全球市場財智列出近期十大沽空比例最高港股

阿斯达克财经

恒瑞醫藥：HRS9531注射液獲臨床試驗批准

南方财经网

每日沽空追蹤 | 恒瑞醫藥 03月09日沽空量成交22.36萬股，沽空比例為7.36%

「一哥」也被跨國大藥企「鴿」？NewCo狂熱背後，中國創新藥出海三大真相

Ofweek维科网

恒瑞醫藥、百濟神州快跑，多藥企多點開花！中國創新藥矩陣持續擴容

恒瑞醫藥盤中異動早盤大幅下挫3.06%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":65.2,"timestamp":1773302900004,"preClose":65.85,"halted":0,"volume":1276420,"delay":0,"changeRate":-0.009870918754745505,"floatShares":258000000,"shares":6637000000,"eps":1.1381407471763683,"marketStatus":"已收盤","change":-0.65,"latestTime":"03-12 16:08:20","open":66,"high":66.2,"low":64.5,"amount":83039010,"amplitude":0.025816,"askPrice":65.2,"askSize":22600,"bidPrice":65.05,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.3204799999999997,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1773365400000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":65.85,"openAndCloseTimeList":[[1773279000000,1773288000000],[1773291600000,1773302400000]],"volumeRatio":0.4215,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":55.3,"timestamp":1773298800000,"preClose":55.83,"halted":0,"volume":26669100,"delay":0,"premium":"+3.59"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.37%","roe":"14.34%","lyrEps":1.138141,"volumeRatio":0.4215,"shares":6637000000,"dividePrice":0,"high":66.2,"amplitude":0.025816,"preClose":65.85,"low":64.5,"week52Low":52.5,"pbRate":"6.39","psRate":"12.27","week52High":95.2,"institutionHeld":0,"latestPrice":65.2,"committee":-0.965217,"eps":1.1381407471763683,"divideRate":0,"volume":1276420,"delay":0,"ttmEps":1.3204799999999997,"open":66,"prevYearClose":71.25,"prevWeekClose":65.35,"prevMonthClose":66.5,"prevQuarterClose":71.25,"fiveDayClose":62.35,"twentyDayClose":69.05,"sixtyDayClose":75.15,"earningDate":1774454400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1772208000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-03-11","current":49.233004,"percent":0.030151,"low":46.986716,"twenty":51.767885,"median":55.22616,"eighty":60.603,"high":65.582363,"avg":55.998625,"sd":4.528533,"marketCap":421818178494.24},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-11","current":49.566433,"twenty":51.767885,"median":55.22616,"eighty":60.603,"marketCap":421818178494.24}],"updateTime":1773294960815},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618902170","title":"世界腎臟日｜警惕「沉默殺手」，藥企競速「護腎」","url":"https://stock-news.laohu8.com/highlight/detail?id=2618902170","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618902170?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 12:03","pubTimestamp":1773288195,"startTime":"0","endTime":"0","summary":"今年3月12日迎来第21个世界肾脏日，主题为“人人享有肾脏健康：关爱生命，守护地球”，强调个体健康与环境保护的双重关注。更值得警惕的是，CKD起病隐匿，早期常无明显症状，被称为“沉默的杀手”。此外，通过肾脏B超检查，能够观察肾脏形态和结构，排查囊肿、结石等问题。在此背景下，国内外药企加速布局肾病赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","01276","LU1023057109.AUD","03692","LU0359201612.USD","BK1191","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2618902199","title":"14億歐元BD終止！恒瑞被默克\"退貨\"的背後……","url":"https://stock-news.laohu8.com/highlight/detail?id=2618902199","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618902199?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 07:31","pubTimestamp":1773271895,"startTime":"0","endTime":"0","summary":"根据协议条款，恒瑞可获得总计高达14亿欧元的首付款、里程碑付款及销售分成，其中首付款1.6亿欧元在协议生效后即落入恒瑞囊中。02终止是“瘦身计划”一环默克此次终止合作的决策，并非针对恒瑞单一个案。值得注意的是，尽管合作终止，但合同并未约定退款条款。从更宏观的视角看，此次终止合作是默克战略调整的必然结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312073613a4623b0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312073613a4623b0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU2543165471.USD","BK1191","LU1023057109.AUD","LU0359201885.HKD","01276","LU0359202008.SGD"],"gpt_icon":0},{"id":"2618407549","title":"穩字當頭：恒瑞醫藥換屆稍欠鋭氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2618407549","media":"财中TMT","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618407549?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 18:58","pubTimestamp":1773226708,"startTime":"0","endTime":"0","summary":"3月3日，换届公告披露后的首个交易日，恒瑞医药A股收跌1.71%、港股收跌2.34%。2021年更成为恒瑞医药的大考年。这一年，恒瑞医药失去A股医药市值第一的荣耀。危急关头，已卸任近一年半的创始人孙飘扬，于2021年7月重返恒瑞医药，再度掌舵。财报数据显示，2025年三季度末，恒瑞医药合同负债余额从1.60亿元增至39.71亿元。2026年以来，截至目前，公开信息暂无恒瑞医药对外授权合作的新披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311194427a6b80d81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311194427a6b80d81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359201885.HKD","BK1191","LU1023057109.AUD","LU2543165471.USD","LU0359202008.SGD","01276"],"gpt_icon":0},{"id":"2618394021","title":"馮佶，恒瑞醫藥女總裁榮登2026「福布斯中國傑出商界女性100」排行榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2618394021","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618394021?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:55","pubTimestamp":1773222938,"startTime":"0","endTime":"0","summary":"刚刚，恒瑞医药官方发布，2026年3月9日，福布斯正式公布2026“中国杰出商界女性100”榜单，恒瑞医药总裁冯佶女士凭借其卓越的领导力与深厚的行业积淀，荣登2026年榜单，为“她力量”写下生动的时代注脚，也让更多人看见中国女性在医药创新领域持续生长的力量。冯佶，女，1970年出生，籍贯上海，现任恒瑞医药总裁兼首席运营官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031121161297adc483&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031121161297adc483&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","BK1191","LU0359201612.USD","LU1023057109.AUD","01276"],"gpt_icon":0},{"id":"2618024919","title":"今日，康寧傑瑞官宣新CTO！來自恒瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2618024919","media":"药渡","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618024919?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:20","pubTimestamp":1773220800,"startTime":"0","endTime":"0","summary":"此次重磅人事任命，是康宁杰瑞在核心管理团队建设上的重要布局，恰逢公司从创新研发向商业化落地的关键节点。公告显示，其职业履历亮眼，在加入康宁杰瑞之前，职业生涯长期扎根江苏恒瑞医药及旗下子公司，逐步成长为生物药领域核心管理人才。王宏伟博士也对加入康宁杰瑞表达高度期待，他表示，康宁杰瑞作为行业内极具差异化创新能力与高成长潜力的生物制药公司，在双抗及ADC领域的战略布局和快速推进令其印象深刻。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117471097ad7b04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117471097ad7b04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU2543165471.USD","BK1191","LU1023057109.AUD","LU0359201885.HKD","01276","LU0359202008.SGD"],"gpt_icon":0},{"id":"2618940731","title":"恒瑞醫藥海外大單告吹","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940731","media":"股市动态分析","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940731?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:13","pubTimestamp":1773220389,"startTime":"0","endTime":"0","summary":"大单告吹2023年10月30日，恒瑞医药与德国默克达成一项战略授权协议。HRS-1167片为恒瑞医药自主研发的PARP1小分子抑制剂，属于第二代PARP抑制剂，可治疗多种肿瘤疾病，首选适应症为前列腺癌。近日，默克宣布终止与恒瑞医药围绕PARP1抑制剂HRS-1167的全球授权合作。幸运的是，虽然大单告吹，但1.6亿欧元的首付款在2023年交易交割时已全额到账，且协议中无任何首付款退款条款，这笔钱恒瑞医药无需返还。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117195595486399&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117195595486399&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","BK1191","LU0359201612.USD","LU0359202008.SGD","01276","LU0359201885.HKD","LU2543165471.USD"],"gpt_icon":0},{"id":"2618675910","title":"恒瑞醫藥：注射用SHR-9803獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618675910","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618675910?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:07","pubTimestamp":1773220033,"startTime":"0","endTime":"0","summary":"【恒瑞医药：注射用SHR-9803获临床试验批准】恒瑞医药公告，注射用SHR-9803收到国家药品监督管理局签发的《药物临床试验批准通知书》（受理号：CXSL2501078），同意本品联合阿得贝利单抗±贝伐珠单抗±化疗在晚期恶性实体瘤患者中开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113668861077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1580142542.USD","LU1997245177.USD","LU1255011170.USD","LU2543165471.USD","LU2488822045.USD","LU2289578879.USD","BK0060","LU2580892789.USD","LU2097828714.EUR","LU1655091616.SGD","LU2328871848.SGD","LU2097828805.USD","600276","LU0359202008.SGD","LU0405327494.USD","LU1997245094.SGD","LU2097828474.EUR","LU0359201885.HKD","LU1781817850.SGD","01276","LU1328615791.USD","LU1969619763.USD","BK0028","LU2580892862.HKD","LU2097828631.EUR","LU0359201612.USD","BK0196","LU1146622755.USD","BK0239","LU1064130708.USD","BK0012","BK0188","LU1997244956.HKD","LU1064131003.USD","LU0405327148.USD","BK1191","LU2097828557.USD","BK0183","LU2495084118.USD","LU1023057109.AUD","LU1820825898.SGD","LU2148510915.USD"],"gpt_icon":0},{"id":"2618940735","title":"恒瑞醫藥：董事會會議通告","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940735","media":"香港交易所","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940735?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217842,"startTime":"0","endTime":"0","summary":"恒瑞医药于2026年3月11日宣布，将于2026年3月25日（星期三）召开董事会会议，主要议程包括审议及批准公司及其附属公司截至2025年12月31日止年度之全年业绩，并考虑派发末期股息事宜。会议将由董事长孙飘扬先生主持，出席会议的董事会成员包括6名执行董事、1名非执行董事及4名独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031118411497ad8f50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031118411497ad8f50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","01276","BK1191","LU0359201612.USD","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2618757940","title":"每日沽空追蹤 | 恒瑞醫藥 03月11日沽空量成交17.64萬股，沽空比例為13.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618757940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618757940?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217820,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间03月11日，跌0.9%，卖空量成交17.64万股，较上一交易日减少37.8%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163223a460b536&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163223a460b536&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU1023057109.AUD","LU0359201612.USD","BK1191","LU2543165471.USD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2618940753","title":"恒瑞醫藥03月11日主力淨流出114.2萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940753?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 16:15","pubTimestamp":1773216957,"startTime":"0","endTime":"0","summary":"03月11日, 恒瑞医药股价跌0.90%，报收65.85元，成交金额8633.1万元，换手率0.51%，振幅2.11%，量比0.35。恒瑞医药今日主力资金净流出114.2万元，上一交易日主力净流入1296.2万元。该股近5个交易日上涨10.38%，主力资金累计净流入3598.0万元；近20日主力资金累计净流入9178.4万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162056a460abca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162056a460abca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU1023057109.AUD","BK1191","LU2543165471.USD","LU0359202008.SGD","01276","LU0359201612.USD"],"gpt_icon":0},{"id":"2618940752","title":"「醫藥一哥」被放鴿子，又一個國產創新藥BD交易遭「退貨」","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940752","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940752?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 16:06","pubTimestamp":1773216373,"startTime":"0","endTime":"0","summary":"近年来，中国创新药BD交易市场火热。另有报告显示，2026年1—2月中国创新药BD交易总额达532.76亿美元，交易数量达44笔。近日，知名跨国药企默克宣布终止与“医药一哥”恒瑞医药围绕PARP1抑制剂HRS-1167的全球授权合作。而对于恒瑞医药方面，业内指出，这笔合作终止“有得有失”。恒瑞医药的遭遇并非孤例，BD交易可谓是“冰火两重天”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119104197ad9ac2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119104197ad9ac2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","LU0359201885.HKD","BK1574","LU0359202008.SGD","01276","06978","BK1161","09939","LU2543165471.USD","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2618094075","title":"翰森製藥、恒瑞醫藥等齊發力，國產GLP-1類減重藥加速「破圈」","url":"https://stock-news.laohu8.com/highlight/detail?id=2618094075","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618094075?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 11:32","pubTimestamp":1773199961,"startTime":"0","endTime":"0","summary":"据悉，在减重药物领域，GLP-1类药物成为热门赛道，国内一批药企也积极抢占这一赛道，并逐渐迎来收获。除了翰森制药外，还有一批国产GLP-1类新药正在加速推进临床。值得一提的是，目前已有多个国产GLP-1类新药获批上市。从临床推进到上市落地，国产GLP-1类药物的多点突破，彰显了我国生物医药产业的自主创新实力。未来，随着药企持续加大研发投入，聚焦剂型创新、适应症拓展，国产GLP-1类药物将在全球肥胖防控领域发挥更重要的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","BK1191","BK1589","LU2543165471.USD","LU0359201885.HKD","01801","03692","01276","BK1583","LU0359202008.SGD","LU0359201612.USD"],"gpt_icon":0},{"id":"2618940751","title":"減重大戰再添中國玩家：翰森奧萊泊肽III期成功，國產GLP-1/GIP雙靶點加速入場","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940751","media":"E药经理人","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940751?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 21:39","pubTimestamp":1773149950,"startTime":"0","endTime":"0","summary":"中国本土企业在GLP-1双靶点减重药领域正加速追赶全球第一梯队。据悉，奥莱泊肽凭借双靶点协同作用的创新设计，恶心发生率平均不到10%，呕吐发生率平均不到5%。目前，奥莱泊肽计划近期在中国递交新药上市申请，若进展顺利，有望成为中国GLP-1/GIP双靶点前三获批的产品之一。恒瑞医药的HRS9531是GLP-1/GIP双靶点注射剂，减重适应证上市申请已于2025年9月获NMPA受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310214535a45ec777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310214535a45ec777&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","01276","LU1023057109.AUD","BK1191","LU2543165471.USD","BK1583","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","03692"],"gpt_icon":0},{"id":"2618886639","title":"多家藥企臨床獲批 / 受理，創新藥行情要啓動？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618886639","media":"E药资本界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618886639?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 12:01","pubTimestamp":1773115309,"startTime":"0","endTime":"0","summary":"2026 年3月以来，医药生物板块捷报频传，复星医药、科伦药业、君实生物、恒瑞医药等多家龙头及创新药企密集披露临床进展公告，覆盖新药临床试验获批、上市申请受理等关键节点。恒瑞医药 亦于近日发布公告，获得药物临床试验批准通知书，在创新药研发赛道持续深耕。随着更多新药进入临床关键阶段或获批上市，将为企业带来新的业绩增长点，同时也将推动医药生物板块向创新驱动转型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310121244a6b4327e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310121244a6b4327e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU1023057109.AUD","LU2543165471.USD","BK1161","LU0359201612.USD","01276","LU0359202008.SGD","02196","06978","LU0359201885.HKD","BK1574"],"gpt_icon":0},{"id":"2618602152","title":"標普全球市場財智列出近期十大沽空比例最高港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618602152","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618602152?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 10:38","pubTimestamp":1773110280,"startTime":"0","endTime":"0","summary":"标普全球市场财智列出截至上周五在香港十大沽空比例最高港股。数据是根据来自标普全球市场财智的证券金融数据集计算得出。计算沽空的指标为借出股份占已发行股份总数的百分比。沽空资料截至 2026-03-09 16:25。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190627142633458_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190627142633458_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1507847/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1507847/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0149721374.USD","LU0359201612.USD","LU0117844026.USD","LU0588545730.USD","LU0784639295.USD","LU1366334578.USD","BK1522","000063","LU0327786744.USD","02318","LU1981816686.USD","LU0594300419.USD","BK1109","BK1521","LU0140636845.USD","LU0048580855.USD","LU0417516738.SGD","LU0880133367.SGD","LU1188198961.HKD","BK1610","LU0878005551.USD","LU0307460666.USD","02768","LU0823426308.USD","LU2226246903.HKD","LU0890818403.SGD","IE00BYV24P56.USD","LU0106959298.USD","LU0197773673.USD","LU0164880469.USD","LU1807302812.USD","LU0348827113.USD","LU0359202008.SGD","LU2399975544.HKD","LU2543165471.USD","HK0000320264.USD","LU0348735423.USD","LU0831093199.SGD","LU2039709279.SGD","LU1328277881.USD","LU0315178854.USD","LU0348783662.USD","600276","LU0650527681.SGD","BK1191","LU0865486749.SGD","LU0348805143.USD","LU0831103253.SGD","LU0630378429.USD","IE00BVYPNQ40.USD","LU0348825331.USD","LU2152927971.USD","LU0370786039.SGD","LU1282651121.HKD","BK1205","IE00BZ08YS42.EUR","LU0918141705.HKD","BK1116","LU2476274308.USD","LU0384037296.USD","LU1769817096.USD","LU1880383440.USD","IE00B29SXG58.USD","IE00BZ08YR35.GBP","LU1044875133.USD","002050","LU0634319403.HKD","PAImain","LU0320764599.SGD","LU0823426480.USD","BK1518","LU0588545904.SGD","LU0918141887.USD","LU1794554557.SGD","LU2153591404.USD","LU0084288322.USD","LU2778985437.USD","SG9999011746.SGD","82318","BK1219","LU0417516571.SGD","LU0862451753.SGD","IE00BVYPNP33.GBP","LU0164872284.USD","LU0572944931.SGD","LU0640798160.USD","LU0675040207.SGD","LU0762542818.HKD","LU0882747503.HKD","01072","03145","SG9999014674.SGD","LU0531971595.HKD","LU0348788117.USD","LU1960683339.HKD","601318","LU0072462343.USD","BK1110","LU0328353924.USD","IE0034224299.USD","SG9999001903.USD","LU0051755006.USD","SG9999000459.SGD","BK1103","HK0001040168.HKD","LU0196878994.USD","BK1529","LU0348814723.USD","03750","LU1820825898.SGD","LU0708995583.HKD","LU0797268264.HKD","LU1282649067.USD","LU0228367735.SGD","LU0791590937.USD","BK1589","LU0819123356.HKD","LU0540923850.HKD","LU0611395673.USD","LU0630378692.HKD","LU1831875114.USD","LU0441854154.USD","LU1719994722.HKD","01276","BK1550","LU0762540952.USD","LU1023057109.AUD","LU1105468828.SGD","LU1770034418.SGD","LU1813983027.USD","LU1152091168.USD","LU1282649810.SGD","IE0008369823.USD","LU0067412154.USD","BK1506","LU0561508036.HKD","LU1251922891.USD","BK1546","BK1184","LU1282649141.HKD","LU0244354667.USD","LU1366334651.USD","LU2424517915.HKD","HPAD.SI","LU0315179316.USD","LU1235295612.USD","LU2293587155.HKD","LU2348773727.SGD","LU0651947912.USD","LU0165289439.USD","BK1505","IE0008368742.USD","LU0072913022.USD","LU0588545490.SGD","LU1048596156.SGD","SG9999004220.SGD","LU0607220059.USD","LU0054450605.USD","LU0488056044.USD","HK0000306685.HKD","LU0197773160.USD","BK1590","LU0828237510.HKD","IE0003895053.USD","LU1046422090.SGD","BK1597","LU1008478684.HKD","BK1516","HK0000306701.USD","002768","LU1303224171.USD","LU0314109678.HKD","LU0149534421.HKD","BK1535","LU0348783233.USD","LU1044876610.USD","LU0163747925.USD","LU0049853897.USD","LU1051768304.USD","SG9999001440.SGD","LU1642822792.SGD","02013","BK1526","LU0651946864.USD","LU1282651048.USD","02050","LU0359201885.HKD","LU1051769294.HKD","00763","LU0011963245.USD","LU0588546209.SGD","IE00BF5LJ272.USD","SG9999002828.SGD","LU2348774022.SGD","01951","HK0000320223.HKD","LU1152091754.HKD","SG9999002463.SGD","LU1115378108.SGD","LU0181495838.USD","LU0348784397.USD","PNGAY","LU0456827905.SGD","BK1149","LU0762541174.USD","IE00BMCWC346.EUR","LU0211977185.USD","LU0828237940.HKD","LU0293314216.USD","BK1607","LU0052750758.USD","SG9999002562.SGD","IE0032431581.USD","LU2476274720.SGD","600875","LU1481107354.HKD","LU0210527791.USD","LU0501845795.SGD","LU0898667661.SGD","LU1211504680.USD","LU1224444064.USD","LU0326950275.SGD","LU0049112450.USD","LU0821914370.USD","LU0862451837.USD","601919","LU0039217434.USD","LU0605514214.HKD","LU0819121731.USD","LU1044874839.SGD","LU1226287529.USD","LU0878004406.USD","LU0791591158.USD","LU0348816934.USD","IE00B031HY20.USD","LU0235996351.USD","LU0254981946.USD","LU0417516902.SGD","BK1240","LU1515016050.SGD","LU1720050803.USD","LU1961090484.USD","LU1993786604.SGD","LU1769817179.HKD","IE00BGHQDM52.EUR","LU1880383366.USD","LU0228659784.USD","BK1507","LU1048588211.SGD","LU0856984785.SGD","300750","LU0449515922.USD","LU0106252389.USD","LU0648948544.HKD","BK1583","LU1146622755.USD","BK1183","LU0594300179.USD","01919","LU2153592121.USD","IE00BZ08YT58.USD","LU1655091459.SGD","LU1282648689.USD","LU0043850808.USD","LU0871576103.HKD","LU0463099449.HKD","LU0164865239.USD"],"gpt_icon":1},{"id":"2618641017","title":"恒瑞醫藥：HRS9531注射液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618641017","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618641017?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 17:27","pubTimestamp":1773048469,"startTime":"0","endTime":"0","summary":"南财智讯3月9日电，恒瑞医药公告，HRS9531注射液收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意本品开展慢性肾脏病（CKD）的临床试验。通知书审批结论显示，该申请于2025年12月9日受理，符合药品注册有关要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666153269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327494.USD","LU1655091616.SGD","BK0060","LU1969619763.USD","BK0028","LU1580142542.USD","LU0359202008.SGD","LU2148510915.USD","LU2543165471.USD","LU2580892862.HKD","600276","LU1820825898.SGD","LU2097828805.USD","01276","LU0359201612.USD","LU2097828557.USD","BK0196","BK0012","LU1023057109.AUD","LU1328615791.USD","LU1997245177.USD","LU0405327148.USD","LU1064131003.USD","LU1781817850.SGD","LU2328871848.SGD","LU2488822045.USD","LU0359201885.HKD","LU1255011170.USD","LU1997245094.SGD","LU1064130708.USD","LU1146622755.USD","LU2097828714.EUR","LU2289578879.USD","LU2580892789.USD","LU2097828631.EUR","BK0239","LU2097828474.EUR","BK0183","LU2495084118.USD","LU1997244956.HKD","BK0188","BK1191"],"gpt_icon":0},{"id":"2618104674","title":"每日沽空追蹤 | 恒瑞醫藥 03月09日沽空量成交22.36萬股，沽空比例為7.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618104674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618104674?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 16:30","pubTimestamp":1773045020,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间03月09日，跌0.92%，卖空量成交22.36万股，较上一交易日减少76.18%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163226a6b1c5e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163226a6b1c5e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359201612.USD","LU0359201885.HKD","BK1191","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD"],"gpt_icon":0},{"id":"2618741966","title":"「一哥」也被跨國大藥企「鴿」？NewCo狂熱背後，中國創新藥出海三大真相","url":"https://stock-news.laohu8.com/highlight/detail?id=2618741966","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618741966?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 14:05","pubTimestamp":1773036312,"startTime":"0","endTime":"0","summary":"NewCo正帮助中国创新药企实现资本和临床双加速，书写新的全球化进程。退货未止，新潮已起。当License-out不再是唯一选择，NewCo能否成为中国创新药新的全球化解法？“一哥”也被鸽？但到了2025年，无论从中国创新药的管线质量，还是MNC所面临的战略环境来看，情况早已大相径庭。其中，NewCo交易持续升温。数据显示，2025年NewCo交易数量再创新高，达到13笔，总金额超过100亿美元。“NewCo本身就是一种长期价值共享机制，通过股权放大未来潜在收益。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309140533a6b15099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309140533a6b15099&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","BK1574","01276","LU0359201612.USD","06978","BK1161","BK1191","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD"],"gpt_icon":0},{"id":"2618118576","title":"恒瑞醫藥、百濟神州快跑，多藥企多點開花！中國創新藥矩陣持續擴容","url":"https://stock-news.laohu8.com/highlight/detail?id=2618118576","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618118576?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 10:27","pubTimestamp":1773023252,"startTime":"0","endTime":"0","summary":"在新药上市方面，恒瑞医药坚持差异化研发策略，以临床需求为导向，利用技术平台打造差异化创新产品矩阵，已经有20多个1类创新药获批上市。2025年上半年，公司创新药销售及许可收入95.61亿元，占公司营业收入比重60.66%。据悉，百济神州不断扩大百泽安的全球市场，持续拓展其适应症和报销覆盖，百泽安目前已在全球超过50个市场获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091102039545a61e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091102039545a61e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","LU0359201612.USD","BK1161","LU1023057109.AUD","BK1583","LU1303224171.USD","LU1251922891.USD","BK1500","LU2328871848.SGD","LU0588546209.SGD","LU1770034418.SGD","06978","LU1969619763.USD","LU0359201885.HKD","BK1588","LU2543165471.USD","01276","06160","LU1719994722.HKD","LU0359202008.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2618674482","title":"恒瑞醫藥盤中異動 早盤大幅下挫3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618674482?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 09:51","pubTimestamp":1773021107,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时51分，恒瑞医药股票出现波动，股价快速下挫3.06%。截至发稿，该股报63.350港元/股，成交量43.6万股，换手率0.17%，振幅3.14%。恒瑞医药股票所在的药品行业中，整体跌幅为1.19%。其相关个股中，劲方医药-B、海西新药、康臣药业涨幅较大，振幅较大的相关个股有宝济药业-B、长风药业、海西新药，振幅分别为29.68%、26.89%、13.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603090951489545937b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603090951489545937b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","LU1023057109.AUD","LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD","01276"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}